These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 37698225)
21. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma. Xu M; Mu J; Wang J; Zhou Q; Wang J Front Oncol; 2022; 12():961213. PubMed ID: 35965536 [TBL] [Abstract][Full Text] [Related]
22. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP Front Immunol; 2022; 13():933973. PubMed ID: 36045691 [TBL] [Abstract][Full Text] [Related]
23. The role of a cuproptosis-related prognostic signature in colon cancer tumor microenvironment and immune responses. Xu C; Liu Y; Zhang Y; Gao L Front Genet; 2022; 13():928105. PubMed ID: 36313449 [No Abstract] [Full Text] [Related]
24. A Prognostic Cuproptosis-Related LncRNA Signature for Colon Adenocarcinoma. Zhong L; Zhu J; Shu Q; Xu G; He C; Fang L J Oncol; 2023; 2023():5925935. PubMed ID: 36844874 [TBL] [Abstract][Full Text] [Related]
25. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer. Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X Front Oncol; 2023; 13():1083956. PubMed ID: 37384293 [TBL] [Abstract][Full Text] [Related]
26. Cuproptosis-related genes signature and validation of differential expression and the potential targeting drugs in temporal lobe epilepsy. Yang X; Zhang X; Shen K; Wang Z; Liu G; Huang K; He Z; Li Y; Hou Z; Lv S; Zhang C; Yang H; Liu S; Ke Y Front Pharmacol; 2023; 14():1033859. PubMed ID: 37435496 [No Abstract] [Full Text] [Related]
27. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell. Sun Y; Yao L; Man C; Gao Z; He R; Fan Y Front Immunol; 2023; 14():1220760. PubMed ID: 37822927 [TBL] [Abstract][Full Text] [Related]
28. Identification of two molecular subtypes and a novel prognostic model of lung adenocarcinoma based on a cuproptosis-associated gene signature. Zhou J; Chen D; Zhang S; Wang C; Zhang L Front Genet; 2022; 13():1039983. PubMed ID: 36712848 [TBL] [Abstract][Full Text] [Related]
29. A cuproptosis-related lncRNA signature to predict prognosis and immune microenvironment of colon adenocarcinoma. Li D; Qu G; Ling S; Sun Y; Cui Y; Yang Y; Cao X Sci Rep; 2023 Apr; 13(1):6284. PubMed ID: 37072493 [TBL] [Abstract][Full Text] [Related]
30. Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients. Peng H; Zou Z; Xiang Z; Lu X; Zhang Y; Peng X Medicine (Baltimore); 2023 Aug; 102(34):e34741. PubMed ID: 37653738 [TBL] [Abstract][Full Text] [Related]
31. Cuproptosis-Related Genes Are Associated with Cell Cycle and Serve as the Prognostic Signature for Clear Cell Renal Cell Carcinoma. Guo T; Zhang J; Yuan Z; Tang H; Wang T; Wang X; Chen S J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556123 [TBL] [Abstract][Full Text] [Related]
32. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma. Gao H; Xing F BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131 [TBL] [Abstract][Full Text] [Related]
33. A novel enterocyte-related 4-gene signature for predicting prognosis in colon adenocarcinoma. Cheng X; Wei Y; Fu Y; Li J; Han L Front Immunol; 2022; 13():1052182. PubMed ID: 36532007 [TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer. Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115 [TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of cuproptosis-related long noncoding RNA for predicting prognostic and diagnostic value and immune landscape in colorectal adenocarcinoma. Liu S; Zhang S; Liu Y; Yang X; Zheng G Hum Genomics; 2023 Mar; 17(1):22. PubMed ID: 36915193 [TBL] [Abstract][Full Text] [Related]
36. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201 [TBL] [Abstract][Full Text] [Related]
37. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. Yan C; Niu Y; Ma L; Tian L; Ma J J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876 [TBL] [Abstract][Full Text] [Related]
38. Construction of a prognostic model based on genes associated with mitochondrial energy metabolic pathway in colon adenocarcinoma and its clinical significance. Zhang X; Liang C; Zhou B; Pang L J Mol Recognit; 2023 Aug; 36(8):e3044. PubMed ID: 37322568 [TBL] [Abstract][Full Text] [Related]
39. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma. Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y Front Immunol; 2022; 13():1038927. PubMed ID: 36451813 [TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC. Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J Front Genet; 2023; 14():1094793. PubMed ID: 36891150 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]